Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.41 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.41 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.41 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.41 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.41 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.41 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.41 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14468610 | 0.86 | MAOA (0.43) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL14447677 | 0.85 | PRKDC (0.48) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL14802155 | 0.84 | MAOA (0.49) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5454450 | 0.84 | PRKDC (0.48) | PRKDCMAOAGAA | |
| SCHEMBL5448690 | 0.83 | PRKDC (0.45) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5446244 | 0.80 | MAOA (0.64) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL5451016 | 0.79 | PRKDC (0.41) | PRKDCPIK3CGP2RY12ATM | |
| SCHEMBL5440522 | 0.78 | PRKDC (0.48) | PRKDCGAA | |
| SCHEMBL5446315 | 0.78 | MAOA (0.64) | PRKDCMAOAATP1A1ATP1B1ATP1A3 | |
| SCHEMBL14802146 | 0.78 | PRKDC (0.47) | PRKDCMAOAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1660473-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | Luitpold Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004085418-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | LUITPOLD PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | PRKDC 12/4885MAOA 4539/4885ATP1A1 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.